The British Menopause Society, Royal College of Obstetricians and Gynaecologists and the Society for Endocrinology have produced this joint position statement to provide guidance to healthcare practitioners who offer care to women experiencing the menopause.
Hip and knee osteoarthritis (HKOA) is a chronic disease characterized by joint pain that leads to reduced physical function and health-related quality of life (HRQoL). At present, no cure is available.
Menopause marks the end of female reproductive capacity. It is defined as the point after cessation of the menstrual cycle for 12 months (Nursat et al., 2008).
Corticosteroid (glucocorticoid). Depo-Medrone with Lidocaine is indicated in conditions requiring a glucocorticoid effect: e.g. anti-inflammatory or anti-rheumatic. It is recommended for local use where the added anaesthetic effect would be considered advantageous. Depo-Medrone with Lidocaine may be used as follows: Intra-articular administration Rheumatoid arthritis Osteo-arthritis with an inflammatory component Periarticular administration Epicondylitis Intrabursal administration Subacromial bursitis Prepatellar bursitis Olecranon bursitis Tendon sheath administration Tendinitis Tenosynovitis Epicondylitis Therapy with Depo-Medrone with Lidocaine does not obviate the need for the conventional measures usually employed. Although this method of treatment will ameliorate symptoms, it is in no sense a cure and the hormone has no effect on the cause of the inflammation.
Objectives: To explore the relative contribution of cumulative physical workload, sociodemographic and lifestyle factors, as well as prior injury to hospitalization due to knee and hip OA.
An investigational oral drug called ONO-4641 which is in joint development by Ono Pharma and Merck Serono, reduced the number...
Eli Lilly and Company has announced that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of...
Background: Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women as options are scarce for those who cannot or do not want to take hormone therapy.
Local or regional anaesthesia with bupivacaine is indicated for: - Surgical operations, including obstetric operations such as Caesarean section. - Acute pain relief, including labour or postoperative pain. - Diagnosis and treatment of chronic pain, e.g. sympathetic nerve blocks. Bupivacaine can be used for different anaesthetic techniques including local infiltration, minor and major nerve blocks and epidural blockade. • Surgical anaesthesia in adults and children above 12 years of age. • Acute pain management in adults, infants and children above 1 year of age.
With life expectancy for women on the rise, most women will experience menopausal transition and spend a significant number of years of their life in the menopausal phase.